Next Generation Immune Modulators
Dualyx is a Ghent-based biotech company dedicated to the development of novel Treg based therapies to address the needs of patients with difficult-to-treat autoimmune diseases. The company was founded in 2020 by Luc van Rompaey in a collaborative model with Wurzburg University, Argenx, VIB, Ghent University and KU Leuven. Dualyx has developed a pipeline of highly promising immune modulating programs including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2) which is currently in IND-enabling studies. TNFR2 is widely regarded as a master control switch in for immunosuppression, making it highly attractive for Treg therapies. Dualyx also has a pipeline of additional Treg programs in early development. Dualyx is backed by a group of well-respected investors including: Fountain Healthcare Partners, Forbion, Andera Partners, V-Bio Ventures, BGV, PMV, VIB, HTGF and GFF.
Science
Dualyx is developing unique immune modulators targeting the in vivo expansion of regulatory T cells. Increasing and activating potent Treg cells can restore the ratio of regulatory to effector T cells and suppress the unwanted autoimmune reaction to achieve long-lasting or even curative treatments in autoimmune disease patients. Through our state-of-art antibody engineering we have developed a pipeline of multi-specific antibodies modulating highly attractive drug targets. These multi-specific antibodies selectively expand and activate Tregs without activating other immune cells. Dualyx’ innovative antibodies thereby hold the promise of combining effective immune suppression with favorable tox profiles and high therapeutic indices. We are developing our pipeline together with industry and academic partners such as argenx, Wurzburg University, KU Leuven and VIB.
We aim to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity and improved patient outcomes than traditional therapeutics.
Pipeline
Dualyx' lead program DT-001 is modulating the validated immune suppression target TNF receptor 2. TNFR2 is highly expressed on Tregs and is regarded as a master control switch for immune suppression, which makes it a very effective target for an antibody agonist. DT-001 is currently in IND enabling studies. It has shown significant and selective Treg expansion in multiple species and we obtained in vivo proof of concept in aggressive GvHD models. DT-001 holds the promise to be applicable for a wide range of auto immune diseases.
The DT-002 programs develops an antibody directed at a well known target and will finalize lead optimization by end 2023. DT-003 is a novel program targeting a new immunological pathway, showing highly attractive data, and entered the lead optimization phase.
Partners
Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic
May 15 2023, Ghent, Belgium
Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic
-
Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its pipeline of Treg candidates
-
Financing co-led by Fountain Healthcare Partners, Forbion and Andera Partners with support from existing investors
-
Bernard Coulie appointed as Independent Chairman with immediate effect
Dualyx NV, a Ghent based biotech developing next generation immune modulators, today announces that it has completed a €40 million ($44 million) Series A financing.